Quality research in the radiopharmaceutical sector encompasses the systematic design, validation, and execution of analytical methods, stability studies, and quality control protocols that ensure every batch of radioactive drug product meets stringent safety, identity, purity, and potency standards before reaching the patient. As a dedicated Radiopharmaceutical CRDMO and CRO, Protheragen offers comprehensive Quality Research Services that integrate validated analytical methodologies, robust stability programs, and phase-appropriate GMP quality systems to support the development, manufacturing, and regulatory approval of innovative radiopharmaceuticals and theranostic agents.
Quality research in radiopharmaceutical development is a specialized discipline that ensures every investigational or commercial radiopharmaceutical product conforms to predefined specifications for safety, efficacy, and consistency. Unlike conventional pharmaceuticals, radiopharmaceuticals present unique quality challenges due to their radioactive nature, short half-lives, and the necessity of administering products before all quality control tests—such as sterility and endotoxin assays—can be completed. This reality places extraordinary emphasis on process validation, environmental monitoring, and the qualification of equipment and analytical methods as the primary safeguards of product quality. Quality research activities encompass the development and validation of analytical methods for radiochemical purity, chemical purity, radionuclidic identity, specific activity, and impurity profiling; the design and execution of stability studies under ICH guidelines to establish shelf life and storage conditions; the implementation of batch release criteria that balance clinical urgency with patient safety; and the continuous monitoring of manufacturing processes through in-process controls, deviation investigations, and corrective and preventive actions (CAPA).
Fig 1. Clinical translation of radiopharmaceuticals. (Korde, Aruna, et al., 2022)
The quality control of radiopharmaceuticals demands a comprehensive testing framework that addresses both conventional pharmaceutical attributes and radiation-specific parameters. Due to the short half-lives of many radioisotopes, certain tests—particularly sterility and bacterial endotoxin—may be performed post-release, making pre-release testing and process validation paramount. The table below summarizes the essential quality control parameters, their analytical methods, and strategic considerations for ensuring radiopharmaceutical quality throughout the product lifecycle.
| QC Parameter | Analytical Method & Acceptance Criteria | Strategic Considerations |
|---|---|---|
| Radiochemical Purity (RCP) | Radio-TLC (rapid, routine); radio-HPLC (high resolution, quantitative); acceptance typically >90–95% depending on monograph. | Critical for patient safety and image quality; two-system radio-TLC improves certainty; HPLC preferred for complex impurity profiles. |
| Radionuclidic Identity & Purity | Gamma spectrometry for energy peak verification; half-life determination; alpha spectrometry for alpha emitters (e.g., Ac-225). | Confirms correct isotope and absence of long-lived contaminants; essential for dosimetry accuracy and waste management. |
| Chemical Identity & Purity | HPLC with UV or MS detection; comparison with cold standard retention time; acceptance varies by product. | Ensures vector integrity; identifies unlabeled precursor, degradation products, and synthetic impurities. |
| Molar Activity (Specific Activity) | Calculated from radioactivity and mass quantification (UV-HPLC or MS); typically ≥1 Ci/μmol or 37 GBq/μmol for diagnostics. | High molar activity prevents receptor saturation; must be validated and monitored across production batches. |
| pH | pH meter or validated indicator strips; typical acceptance range 4.5–8.5 for most parenteral radiopharmaceuticals. | Compatible with both radiolabeling chemistry and physiological tolerance; ethanol-containing formulations require approximate readings. |
| Sterility | Membrane filtration sterility test (14-day culture); filter integrity test (bubble point) as rapid pre-release surrogate. | Often performed post-release due to short half-life; robust aseptic process validation and environmental monitoring are essential. |
| Bacterial Endotoxins | Limulus Amebocyte Lysate (LAL) assay; kinetic chromogenic or turbidimetric methods; limit typically <5–175 EU/vial. | Rapid testing methods are preferred for short-lived products; must meet same standards as licensed pharmaceuticals. |
| Residual Organic Solvents | Gas chromatography (GC); limits per ICH Q3C (e.g., MeCN <4.1 mg/day, EtOH <50 mg/day, DMSO <50 mg/day). | Common impurities from synthesis and purification; ethanol may also serve as stabilizer and requires assay-level quantification. |
| Residual Kryptofix 222 | Color spot test (Ph. Eur.) or validated GC/HPLC method; limit <50 μg/mL (USP) or 2.2 mg/vial (EP). | Crown ether used in ¹⁸F synthesis; must be controlled due to potential toxicity; non-pharmacopoeial methods require full validation. |
| Filter Integrity | Bubble-point test with pressure gauge transducer; acceptance >45 psi or per manufacturer specification. | Serves as rapid sterility surrogate pre-release; critical for aseptic processing confidence in short-timeline production. |
| Appearance & Particulates | Visual inspection; must be clear, colorless, and free from visible particulates or aggregates. | Performed on every vial prior to release; particulates may indicate synthesis failure, purification issues, or environmental contamination. |
| Stability (Real-Time & Accelerated) | Radio-TLC and radio-HPLC at defined timepoints; appearance, pH, and filter integrity monitored; duration aligned with half-life. | Short-lived nuclides (e.g., ⁶⁸Ga) may require only hours of data; long-lived nuclides (e.g., ⁸⁹Zr, ²²⁵Ac) need extended analysis. |
Protheragen delivers comprehensive Quality Research Services tailored specifically for the radiopharmaceutical industry, integrating validated analytical methodologies, ICH-compliant stability programs, and phase-appropriate GMP quality systems to ensure that every batch of radiopharmaceutical product meets the highest standards of safety, purity, and regulatory compliance. From analytical method development and validation through batch release management and post-market stability monitoring, our integrated CRDMO and CRO platform provides sponsors with the specialized expertise, infrastructure, and documentation necessary to navigate the unique quality challenges of radioactive drug development and achieve efficient regulatory approval.
We conduct full pre-release testing of radiopharmaceuticals covering radiochemical, radionuclidic and chemical purity, molar activity, pH and sterility indicators. Authorized reviewers audit all batch documents to approve release, fully complying with FDA, EU and WHO radiopharmaceutical GMP standards.
We build and validate full QC test methods including radio-HPLC, radio-TLC, gamma spectrometry, ICP-MS and LAL endotoxin assays following ICH Q2(R1). Complete validation packages support IND/CTA regulatory inspections.
We design ICH-aligned real-time and accelerated stability trials tailored to radionuclide half-lives. Multi-timepoint testing tracks purity and formulation stability, with statistical analysis to set valid shelf-life limits for regulatory filing.
We build standardized QMS with SOPs, deviation and CAPA workflows. Our team carries out internal and supplier audits, FMEA risk evaluation, and prepares full CMC documentation to pass global regulatory inspections.
Protheragen combines deep radiopharmaceutical expertise with integrated CRDMO and CRO capabilities to deliver Quality Research Services that meet the highest standards of analytical precision, regulatory compliance, and operational reliability. Our multidisciplinary teams understand the unique quality challenges of radioactive drug products—from short half-life logistics and radiolytic degradation to multi-agency regulatory oversight—enabling us to provide seamless, end-to-end support for programs at every stage of development.
Whether you are developing a novel diagnostic radiotracer, advancing a therapeutic radiopharmaceutical toward clinical trials, or seeking a strategic partner to establish validated quality systems and regulatory-compliant batch release processes, Protheragen is ready to support your program with the analytical expertise, quality infrastructure, and regulatory guidance it deserves. Reach out to us today to discuss how our Quality Research Services can ensure the safety, purity, and compliance of your radiopharmaceutical products. Contact our quality strategy team to schedule a consultation and explore a tailored partnership approach.
Reference